<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamaseproducing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR)</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-01-23">23 January 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Dr</roleName><forename type="first">C</forename><surname>Gudiol</surname></persName>
							<email>cgudiol@iconcologia.net</email>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Royo-Cebrecos</surname></persName>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Tebe</surname></persName>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Abdala</surname></persName>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Akova</surname></persName>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Álvarez</surname></persName>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Maestro-De La Calle</surname></persName>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Cano</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">Reina Sofía University Hospital-IMIBIC-UCO</orgName>
								<address>
									<settlement>Córdoba</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Cervera</surname></persName>
							<affiliation key="aff1">
								<orgName type="institution">University Hospital of Alberta</orgName>
								<address>
									<settlement>Edmonton</settlement>
									<region>Alberta</region>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Clemente</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Digestive Transplant Service</orgName>
								<orgName type="institution" key="instit1">Infectious Disease Consultant</orgName>
								<orgName type="institution" key="instit2">Hospital das Clínicas</orgName>
								<orgName type="institution" key="instit3">Universidade Federal Minas Gerais</orgName>
								<address>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Martín-Dávila</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Infectious Diseases Department</orgName>
								<orgName type="institution">Ramon y Cajal Hospital</orgName>
								<address>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Freifeld</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Infectious Diseases Section</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">University of Nebraska Medical Center</orgName>
								<address>
									<settlement>Omaha</settlement>
									<region>Nebraska</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Gómez</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">University Hospital Mútua de Terrassa</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Gottlieb</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Microbiology &amp; Infectious Diseases</orgName>
								<orgName type="institution">Concord Hospital</orgName>
								<address>
									<settlement>Concord</settlement>
									<region>New South Wales</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Gurguí</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution" key="instit1">Infectious Diseases Unit, Hospital de la Santa Creu i Sant Pau and Instituto de Investigación Biomédica Sant Pau</orgName>
								<orgName type="institution" key="instit2">Universitat Autònoma de Barcelona</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Herrera</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Infectious Diseases Section</orgName>
								<orgName type="department" key="dep2">Department of Medicine</orgName>
								<orgName type="department" key="dep3">Centro de Educación Médica e Investigaciones Clínicas (CEMIC)</orgName>
								<address>
									<addrLine>Buenos Aires</addrLine>
									<country key="AR">Argentina</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Manzur</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">Infectious Diseases, Hospital Rawson</orgName>
								<address>
									<addrLine>San Juan</addrLine>
									<country key="AR">Argentina</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Maschmeyer</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Hematology, Oncology and Palliative Care</orgName>
								<orgName type="institution">Academic Teaching Hospital</orgName>
								<address>
									<settlement>Klinikum Ernst von Bergmann</settlement>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution">Charité University Medical School</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Y</forename><surname>Meije</surname></persName>
							<affiliation key="aff12">
								<orgName type="department" key="dep1">Infectious Disease Unit</orgName>
								<orgName type="department" key="dep2">Internal Medicine Department</orgName>
								<orgName type="institution">Barcelona Hospital</orgName>
							</affiliation>
							<affiliation key="aff13">
								<orgName type="institution">SCIAS</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Montejo</surname></persName>
							<affiliation key="aff14">
								<orgName type="laboratory">Infectious Diseases Unit</orgName>
								<orgName type="institution">Cruces University Hospital</orgName>
								<address>
									<settlement>Bilbao</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Peghin</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Infectious Diseases Division</orgName>
								<orgName type="institution">Santa Maria Misericordia University Hospital</orgName>
								<address>
									<settlement>Udine</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="department">Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine</orgName>
								<orgName type="institution">University Hospitals Virgen Macarena and Virgen del Rocío-IBiS</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution">University of Seville</orgName>
								<address>
									<settlement>Seville</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="department">Infectious Diseases Department</orgName>
								<orgName type="institution">Vall d&apos;Hebrón University Hospital</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="institution">Hospital Santa Casa de Misericórdia de Porto Alegre</orgName>
								<address>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamaseproducing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR)</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-01-23">23 January 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">6CD5B65D8DB3CA941F33FE9BD0B22699</idno>
					<idno type="DOI">10.1136/bmjopen-2016-013268</idno>
					<note type="submission">Received 30 June 2016 Revised 19 October 2016 Accepted 21 October 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:44+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Clinical efficacy of β-lactam/ β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extendedspectrum β-lactamaseproducing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR).</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Methods and analysis: A multinational, multicentre, observational retrospective study.</s><s>Episodes of BSI due to ESBL-GNB occurring in haematological patients and haematopoietic stem cell transplant recipients with neutropaenia from 1 January 2006 to 31 March 2015 will be analysed.</s><s>The primary end point will be casefatality rate within 30 days of onset of BSI.</s><s>The secondary end points will be 7-day and 14-day casefatality rates, microbiological failure, colonisation/ infection by resistant bacteria, superinfection, intensive care unit admission and development of adverse events.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample size:</head><p><s>The number of expected episodes of BSI due to ESBL-GNB in the participant centres will be 260 with a ratio of control to experimental participants of 2.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics and dissemination:</head><p><s>The protocol of the study was approved at the first site by the Research Ethics Committee (REC) of Hospital Universitari de Bellvitge.</s><s>Approval will be also sought from all relevant RECs.</s><s>Any formal presentation or publication of data from this study will be considered as a joint publication by the participating investigators and will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE).</s><s>The study has been endorsed by the European Study Group for Bloodstream Infection and Sepsis (ESGBIS) and the European Study Group for Infections in Compromised Hosts (ESGICH).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Strengths and limitations of this study</head><p><s>▪ The multicentric design of the study will allow the recording of a large number of episodes.</s><s>▪ The impact of therapy on mortality and other relevant outcomes will be assessed.</s><s>▪ Owing to the retrospective design of the study, some information may be lost.</s><s>▪ We may not be able to control for some measured and unmeasured confounders.</s><s>▪ Enrolling a sufficient number of patients treated with β-lactam/β-lactamase inhibitor combinations may be difficult.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>The recent spread of extended-spectrum β-lactamases (ESBLs) in Enterobacteriaceae has become a serious public health problem worldwide. 1 2</s><s>]<ref type="bibr">[5]</ref><ref type="bibr" target="#b7">[6]</ref> Until recently, carbapenems, which are not affected by ESBLs, were considered the drugs of choice for treating severe infections caused by ESBL producers. 1 2</s><s>For this reason, while clinicians await new antimicrobials with activity against these MDR microorganisms, they have often been forced to use carbapenems as empiric or definitive therapy in patients with suspected or documented infections due to an ESBL-producing organism.</s><s>However, the increasing use of carbapenems is particularly worrisome in a scenario in which carbapenemaseproducing organisms are also emerging as a serious health problem. <ref type="bibr">7 8</ref></s><s>Thus, the search for alternatives to carbapenems for infections caused by ESBL producers is a priority.</s><s>Although ESBL-producing bacteria may also have different resistance mechanisms that restrict the activity of β-lactam/β-lactamase inhibitor (BLBLI) combinations, some of these agents remain active against a considerable proportion of ESBL-producing enterobacteria, particularly Escherichia coli. <ref type="bibr">9 10</ref></s><s>8]<ref type="bibr" target="#b20">[19]</ref> The impact of the minimum inhibitory concentration (MIC) of PTZ on outcomes of patients with these severe infections who receive this regimen has also been questioned. <ref type="bibr">19 20</ref></s><s>ntil now, the efficacy and safety of BLBLI combinations for the treatment of BSI due to ESBL-GNB in HSCT recipients and haematological patients with neutropaenia has not been elucidated.</s><s>These patients are particularly prone to develop life-threatening infections and frequently receive broad-spectrum antibiotics.</s></p><p><s>This study aims to evaluate if BLBLI combinations are as effective as carbapenems for the treatment of ESBL-GNB BSI in this high-risk population.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>OBJECTIVES OF THE STUDY Primary end point</head><p><s>To compare the efficacy of BLBLI combinations with that of carbapenems for the treatment of BSI due to ESBL-GNB in haematological patients with neutropaenia, in terms of a 30-day case-fatality rate.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary end points</head><p><s>To compare the rates of the following events in these two groups of patients: 1. Seven-day and 14-day case-fatality rates.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS AND ANALYSIS Study design</head><p><s>A multinational, multicentre, retrospective, observational cohort study involving the collection of data of patients from 1 January 2006 to 31 March 2015.</s></p><p><s>The study will be conducted in accordance with the STROBE recommendations. <ref type="bibr" target="#b22">21</ref></s><s>udy population Data will be collected on haematological patients with neutropaenia with at least one episode of BSI due to an ESBL-producing Enterobacteriaceae and who receive carbapenems or BLBLI combinations as the empirical or definitive antibiotic therapy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Setting</head><p><s>The study will be conducted at 22 centres from nine different countries: Spain (11 centres), Brazil (3 centres), Argentina (2 centres), Australia (1 centre), Canada (1 centre), Germany (1 centre), Italy (1 centre), Turkey (1 centre) and the USA (1 centre).</s><s>The great majority of participating centres (20) are university hospitals, except for Hospital Rawson in San Juan, Argentina and Barcelona Hospital in Barcelona, Spain.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Selection of cases</head><p><s>Patients will be identified from previous prospective databases or from the records of the microbiology laboratory of each hospital.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inclusion criteria</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exclusion criteria</head><p><s>Patients with any of the following will be excluded from the study: 1. Episodes of polymicrobial BSI.</s></p><p><s>2. Unavailability of key data (data regarding empirical and targeted therapy and mortality).</s><s>3. Episode occurring outside the study period.</s><s>4. Age &lt;18 years.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data collection</head><p><s>Patients' data will be collected retrospectively.</s><s>These data will be obtained from various sources, including patients' electronic records, patients' notes, the hospital laboratory systems and the hospital patient administration system.</s></p><p><s>The following data will be collected for all cases: sex, age, underlying disease and comorbidities, haematological malignancy status, severity of the episode of febrile neutropaenia according to the Multinational Association of Supportive Care in Cancer (MASCC) index score, <ref type="bibr" target="#b23">22</ref> place of acquisition of infection, <ref type="bibr" target="#b24">23</ref> source of BSI, BSI source control status, clinical and microbiological data, duration of neutropaenia, prior therapies received (antibiotics, immunosuppressors, etc), empirical and definitive antimicrobial therapy, reason for change of antimicrobial therapy, duration of each antibiotic therapy, need for intensive care unit admission and mechanical ventilation, persistent BSI, relapse of BSI, colonisation and/or superinfection by resistant organisms, development of other complications, 7-day case-fatality rate, 14-day case-fatality rate, 30-day casefatality rate, and development of adverse events.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definitions</head><p><s>▸ Antimicrobial therapy administered before susceptibility results were available will be considered as empirical therapy, and antibiotic therapy administered afterwards will be considered as definitive.</s><s>▸ Therapy with a BLBLI combination or a carbapenem will be considered as monotherapy if no other drug with activity against Gram-negatives was co-administered, irrespective of the isolate susceptibility.</s><s>▸ Adverse events will include any of the following events: moderate or severe allergic reactions, severe renal impairment, severe liver impairment and seizures.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Participant timeline</head><p><s>The follow-up period will last 1 month after the onset of BSI.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study outcomes and end point assessment</head><p><s>Primary end point ▸ Case-fatality rate at 30 days from onset of BSI.</s></p><p><s>Secondary end points ▸ Seven-day and 14-day case-fatality rates from onset of BSI.</s><s>▸ Time to death, in days.</s><s>▸ Microbiological failure, defined by:</s></p><p><s>-Persistent BSI beyond the first 48 hours of adequate antibiotic therapy.</s><s>-Relapse of BSI within 7 days of treatment discontinuation.</s><s>▸ Rate of colonisation/infection by bacteria resistant to the study antibiotics.</s><s>▸ Rate of superinfection due to any bacteria.</s><s>▸ Rate of intensive care unit admission.</s><s>▸ Rates of adverse events including:</s></p><p><s>-Any adverse event.</s></p><p><s>-Adverse events requiring treatment discontinuation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample size</head><p><s>The total number of episodes of BSI due to ESBL-GNB in the participant centres during the study period will determine the sample size.</s><s>We expect an amount of 260 episodes with a ratio of control to experimental participants of 2. Prior data indicate that the 30-day casefatality rate among controls is 17%.</s><s>Thus, with an α risk of 0.05 and a β risk of 0.2 in a two-sided test, we will be able to detect a true 30-day case-fatality rate of 5% or 32% in exposed participants.</s><s>We will use an uncorrected χ 2 statistic to evaluate this null hypothesis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Patients who were given BLBLI will be compared with those who were treated with carbapenems empirically and/or as definitive therapy.</s><s>Two non-mutually exclusive cohorts will be constructed and analysed separately.</s><s>The empirical therapy cohort (ETC) will include patients who received empirical therapy with BLBLI or carbapenem, and the isolate was susceptible to the empirical antimicrobial administered.</s><s>The definitive therapy cohort (DTC) will include patients who received definitive monotherapy with an active BLBLI or carbapenem.</s></p><p><s>Continuous variables will be compared by means of the Mann-Whitney U test and t-test.</s><s>Qualitative variables will be compared using the χ 2 test, and relative risks and 95% CIs will be calculated.</s></p><p><s>We will use an uncorrected χ 2 statistic to evaluate the primary end point under the null hypothesis of a 30-day case-fatality rate between study groups.</s><s>Mortality survival functions of patients treated with BLBLI or carbapenems will be estimated using Kaplan-Meier curves and compared using a log-rank test.</s><s>Moreover, survival functions will be compared also at days 7, 14 and 30 to detect very early, early or late mortality differences.</s><s>To control for confounding, multivariate analysis will be performed by the Cox proportional hazard model, using time until death as the dependent variable and therapy with BLBLI or carbapenem as the explanatory variable of interest.</s><s>In both cohorts (ETC and DTC), a propensity score for receiving carbapenem as empirical therapy will be added to the model.</s><s>The propensity score-the probability of receiving carbapenem as empirical and/or targeted therapy-will be calculated using a non-parsimonious multivariate logistic regression model in which the outcome variable will be the use of carbapenem as empirical therapy.</s><s>Each patient will be matched to another patient using the nearest participant matching technique.</s><s>The analysis will be performed with the stepwise logistic regression model of R software (R V.3.2.5).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ETHICAL ISSUES</head><p><s>Prior to the initiation of the study at a particular site, approval will be sought from all appropriate regulatory agencies and the local Research Ethics Committees (RECs) to conduct the study in accordance with the local regulatory requirements.</s><s>The study will only use data routinely collected in the time frame January 2006 to March 2015.</s><s>No extra tests or interventions will be undertaken in patients and the study will have no impact on patient care or outcome.</s></p><p><s>The processing of the patients' personal data collected in this study will comply with the European Directive on Data Privacy.</s><s>All data will be collected, stored and processed anonymously (EU Directive 95/46/EC). <ref type="bibr" target="#b25">24</ref></s><s>All data will be stored in a specific database.</s></p><p><s>The protocol (V2.0 15/5/2015) was approved on 21/ 5/2015 by the REC at the first site.</s><s>The need for informed consent and information sheets was waived by the REC because of the retrospective nature of the study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publication plan</head><p><s>Results will be reported at conferences and in peerreviewed publications.</s><s>The first publication is based on data from all sites, and is analysed as stipulated in the protocol with supervision by statisticians.</s><s>Any formal presentation or publication of data collected from this study will be considered as a joint publication by the participating investigators and will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>]<ref type="bibr">[5]</ref><ref type="bibr" target="#b7">[6]</ref> Until recently, carbapenems have been regarded as the drugs of choice for the treatment of serious ESBL-GNB infections such as BSI.</s><s>They have been widely used for the treatment of patients with suspected or documented infections due to these organisms.</s><s>However, their overuse may induce the appearance of resistance to this agent, <ref type="bibr">25 26</ref> thus severely limiting future treatment options.</s><s>This possibility is of particular concern in a scenario in which carbapenemase-producing organisms are also spreading and are adversely compromising patient's outcomes. <ref type="bibr">26 27</ref></s><s>Therefore, it is extremely important to identify therapeutic alternatives to these drugs.</s></p><p><s>2]<ref type="bibr" target="#b14">[13]</ref><ref type="bibr" target="#b15">[14]</ref><ref type="bibr" target="#b16">[15]</ref><ref type="bibr" target="#b17">[16]</ref><ref type="bibr" target="#b18">[17]</ref><ref type="bibr" target="#b19">[18]</ref><ref type="bibr" target="#b20">[19]</ref> In addition, different factors may be involved in the outcomes of patients treated with these drugs, such as type of infection, the 'inoculum effect' to PTZ (ie, diminished activity with the presence of high bacteria inoculum), the impact of the MIC of this drug and the potential increase in efficacy when using high doses. <ref type="bibr">19 20 28</ref></s><s>Moreover, the existing literature includes mainly non-immunocompromised patients, and information is lacking regarding the usefulness of these agents for the treatment of BSI due to ESBL-GNB in high-risk haematological patients with neutropaenia, including HSCT recipients.</s></p><p><s>]<ref type="bibr" target="#b16">[15]</ref><ref type="bibr" target="#b17">[16]</ref><ref type="bibr" target="#b18">[17]</ref><ref type="bibr" target="#b19">[18]</ref><ref type="bibr" target="#b20">[19]</ref> Randomised controlled trials comparing empirical and definitive antibiotic regimens are difficult to perform in this setting.</s><s>Nevertheless, a randomised clinical trial is being undertaken in several Australasian sites, including Singapore (the 'MERINO' trial, registered at http:// www.clinicaltrials.gov;</s><s>NCT02176122), and aims to be completed by 2018.</s><s>Second, most of the published studies involve patients with BSI from the urinary tract, and the results may not be generalisable to patients with other sources of BSI. <ref type="bibr">13-16 19</ref></s><s>4]<ref type="bibr" target="#b16">[15]</ref><ref type="bibr" target="#b17">[16]</ref><ref type="bibr" target="#b18">[17]</ref><ref type="bibr" target="#b19">[18]</ref><ref type="bibr" target="#b20">[19]</ref> Finally, information regarding the MIC for PTZ, <ref type="bibr" target="#b16">[15]</ref><ref type="bibr" target="#b17">[16]</ref><ref type="bibr" target="#b18">[17]</ref> as well as the doses used for each antibiotic, may not be available in all studies. <ref type="bibr">14 16 18</ref></s><s>his study aims to assess the efficacy of BLBLI combinations in comparison with carbapenems for the treatment of high-risk immunocompromised haematological patients with BSI due to ESBL-producing Enterobacteriaceae.</s><s>It is expected to provide important information regarding the usefulness of BLIBLI combinations as carbapenem-sparing antibiotic regimens for infections caused by ESBL-GNB, which represents a key step in the efforts to minimise the spread of carbapenem-resistant microorganisms.</s><s>Information on this issue will be particularly important in a population prone to receive frequent, repeated cycles of broadspectrum antibiotics, and which often presents with serious or life-threatening infections.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>, Bellvitge University Hospital, IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain 2 Duran i Reynals Hospital, ICO, L'Hospitalet de Llobregat, Barcelona, Spain 3 REIPI (Spanish Network for Research in Infectious Disease), Instituto de Salud Carlos III, Madrid, Spain 4 Statistics Advisory Service, Institute of Biomedical Research of Bellvitge, Rovira i Virgili University, L'Hospitalet de Llobregat, Barcelona, Spain 5 Faculty of Medicine, Instituto do Câncer do Estado de São Paulo, University of São Paulo, Sao Paulo, Brazil 6 Hacettepe University School of Medicine, Ankara, Turkey 7 Infectious Diseases Research Group, Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville (IBiS), University of Seville/CSIC/University Hospitals Virgen del Rocio and Virgen Macarena, Seville, Spain 8 Infectious Diseases Unit, Instituto de Investigación Hospital "12 de Octubre" (i+12), "12 de Octubre" University Hospital; School of Medicine, Universidad Complutense, Madrid, Spain</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc><div><p><s>2. Microbiological failure, defined as the presence of at least one of the following criteria: A. Persistent BSI beyond the first 48 hours of adequate antibiotic therapy.</s></p></div></figDesc><table><row><cell cols="4">B. Relapse of BSI within 7 days of treatment</cell></row><row><cell cols="2">discontinuation.</cell><cell></cell><cell></cell></row><row><cell cols="4">3. Colonisation/infection by bacteria resistant to the</cell></row><row><cell>study antibiotics.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="4">4. Any bacterial superinfection other than ESBL-GNB.</cell></row><row><cell cols="3">5. Intensive care unit admission.</cell><cell></cell></row><row><cell cols="3">6. Development of adverse events:</cell><cell></cell></row><row><cell cols="2">A. Any adverse event.</cell><cell></cell><cell></cell></row><row><cell>B. Adverse</cell><cell>events</cell><cell>requiring</cell><cell>treatment</cell></row><row><cell cols="2">discontinuation.</cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Gudiol C, et al. BMJ Open 2017;7:e013268. doi:10.1136/bmjopen-2016-013268 Open Access on May 17, 2022 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2016-013268 on 23 January 2017. Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">on May 17, 2022 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2016-013268 on 23 January 2017. Downloaded from</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="4">Gudiol C, et al. BMJ Open 2017;7:e013268. doi:10.1136/bmjopen-2016-013268 Open Access on May 17, 2022 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2016-013268 on 23 January 2017. Downloaded from</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgements The authors thank the ESGBIS and the ESGICH study groups for supporting the study.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Funding This study was supported by Ministerio de Economía y Competitividad, Instituto de Salud Carlos III-co-financed by European Development Regional Fund 'A way to achieve Europe' ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015).</s></p><p><s>Competing interests JR-B has been a scientific consultant for Merck, AstraZeneca, Achaogen and InfectoPharm, a speaker in accredited educational activities for Merck and AstraZeneca, a recipient of research grants from COMBACTE-NET, COMBACTE-CARE and COMBACTE-MAGNET, funded by the Innovative Medicines Initiative (European Union and EFPIA in kind).</s><s>AF has received research fees from Merck, and from Astellas for data and safety monitoring.</s><s>JC has received lecture fees from Novartis, Astellas, Pfizer, MSD, Janssen and Astra-Zeneca.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval Clinical Research Ethics Committee and Institutional Review</head><p><s>Board of Hospital Universitari de Bellvitge.</s></p><p><s>Provenance and peer review Not commissioned; externally peer reviewed.</s></p><p><s>Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</s><s>See: http:// creativecommons.org/licenses/by-nc/4.0/</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">AM were responsible for identification of the cases and data collection. CT was the statistician in charge of the statistical analysis. CG and JC drafted and revised the manuscript. All authors reviewed and approved the final version of the manuscript</title>
		<author>
			<persName><forename type="first">Collaborators</forename><surname>Isabel Sánchez-Ortega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hospital</forename><surname>Duran Y Reynals</surname></persName>
		</author>
		<author>
			<persName><forename type="first">-</forename><surname>Ico</surname></persName>
		</author>
		<author>
			<persName><surname>Barcelona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nieves</forename><surname>Spain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pere</forename><surname>Larrosa</surname></persName>
		</author>
		<author>
			<persName><surname>Barba</surname></persName>
		</author>
		<author>
			<persName><surname>Barcelona</surname></persName>
		</author>
		<author>
			<persName><forename type="middle">Irene</forename><surname>Spain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Julián Torre-Cisneros ; Madrid</forename><surname>Gracia-Ahufinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rosa</forename><surname>Spain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Javier</forename><surname>Escudero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ramón</forename><surname>López-Jiménez</surname></persName>
		</author>
		<author>
			<persName><surname>Hospital</surname></persName>
		</author>
		<author>
			<persName><surname>Madrid</surname></persName>
		</author>
		<author>
			<persName><surname>Spain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">;</forename><surname>Bassetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cr-C</forename><surname>Cg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Mg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gm-Dlc</forename><surname>Bm</surname></persName>
		</author>
		<author>
			<persName><surname>Ir-C</surname></persName>
		</author>
		<author>
			<persName><surname>Nl</surname></persName>
		</author>
		<author>
			<persName><surname>Mv</surname></persName>
		</author>
		<author>
			<persName><surname>Lls</surname></persName>
		</author>
		<author>
			<persName><surname>Mdn</surname></persName>
		</author>
		<author>
			<persName><surname>Mc</surname></persName>
		</author>
		<author>
			<persName><surname>Ra</surname></persName>
		</author>
		<author>
			<persName><surname>Jalj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Lg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jlj</forename><surname>Re</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pm-D</forename><surname>Mp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Es</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Tg</surname></persName>
		</author>
		<author>
			<persName><surname>Rn</surname></persName>
		</author>
		<author>
			<persName><surname>Hd</surname></persName>
		</author>
		<author>
			<persName><surname>Pho</surname></persName>
		</author>
		<author>
			<persName><surname>Lcp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Kyi</surname></persName>
		</author>
		<author>
			<persName><surname>Cc</surname></persName>
		</author>
		<author>
			<persName><surname>Dk</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099(08)70041-0</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="159" to="166" />
			<date type="published" when="2008">2008</date>
		</imprint>
		<respStmt>
			<orgName>Vall d&apos;Hebrón University Hospital, Barcelona, Spain. Beatriz Mirelis, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Esther Calbo, University Hospital Mútua de Terrassa ; Reina Sofía University Hospital-IMIBIC-UCO, Córdoba, Spain. José Antonio Lepe, Ildefonso Espigado, José Miguel Cisneros, María D Navarro and Marina de Cueto, Virgen del Rocío and Virgen Macarena University Hospitals, Sevilla, Spain. Mirian Vara and Leire López-Soria, Cruces University Hospital, Bilbao, Spain. Manuel Lizasoain and José María Aguado, 12 de Octubre University Hospital ; Santa Maria Misericordia University Hospital ; Hacettepe University School of Medicine ; Instituto do Câncer do Estado de São Paulo, Brazil. Renata Neto Pires, Hospital Santa Casa de Misericórdia de Porto Alegre, Brazil. Dina Kabbani, University Hospital of Alberta</orgName>
		</respStmt>
	</monogr>
	<note>Canada</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Clinical significance of extended-spectrum beta-lactamases</title>
		<author>
			<persName><forename type="first">J</forename><surname>Rodríguez-Baño</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pascual</surname></persName>
		</author>
		<idno type="DOI">10.1586/14787210.6.5.671</idno>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Anti Infect Ther</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="671" to="683" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Trecarichi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tumbarello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Spanu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jinf.2009.02.002</idno>
	</analytic>
	<monogr>
		<title level="j">J Infect</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="299" to="307" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome</title>
		<author>
			<persName><forename type="first">C</forename><surname>Gudiol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Calatayud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Garcia-Vidal</surname></persName>
		</author>
		<idno type="DOI">10.1093/jac/dkp411</idno>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="333" to="341" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Gudiol</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2016-013268</idno>
	</analytic>
	<monogr>
		<title level="j">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e013268</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<idno type="DOI">10.1136/bmjopen-2016-013268on23</idno>
		<ptr target="http://bmjopen.bmj.com/BMJOpen:firstpublishedas10.1136/bmjopen-2016-013268on23" />
		<imprint>
			<date type="published" when="2017-01">May 17. January 2017</date>
		</imprint>
		<respStmt>
			<orgName>Open Access on</orgName>
		</respStmt>
	</monogr>
	<note>Downloaded from</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Kwon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Choi</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00277-012-1631-y</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="533" to="541" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Escherichia coli in patients with cancer</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">E</forename><surname>Ha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">I</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Cha</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ijantimicag.2013.07.018</idno>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="403" to="409" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSACPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries</title>
		<author>
			<persName><forename type="first">B</forename><surname>Albiger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Glasner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Struelens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">45</biblScope>
			<date type="published" when="2015-05">May 2015. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Kumarasamy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Toleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Walsh</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1473-3099(10)70143-2</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="597" to="602" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Hoban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Bouchillon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Hawser</surname></persName>
		</author>
		<idno type="DOI">10.1128/AAC.01808-09</idno>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="3031" to="3034" />
			<date type="published" when="2007">2007-2008. 2010</date>
		</imprint>
	</monogr>
	<note>: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The diversity of Escherichia coli producing extended-spectrum ß-lactamases in Spain: second nationwide study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Díaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hernández-Bello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rodríguez-Baño</surname></persName>
		</author>
		<idno type="DOI">10.1128/JCM.02147-09</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="2840" to="2845" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials</title>
		<author>
			<persName><forename type="first">S</forename><surname>Shiber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yahav</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Avni</surname></persName>
		</author>
		<idno type="DOI">10.1093/jac/dku351</idno>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="41" to="47" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Z</forename><surname>Vardakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Tansarli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">I</forename><surname>Rafailidis</surname></persName>
		</author>
		<idno type="DOI">10.1093/jac/dks301</idno>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="2793" to="2803" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Extended-Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts</title>
		<author>
			<persName><forename type="first">J</forename><surname>Rodríguez-Baño</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Navarro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Retamar</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/cir790</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="167" to="174" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jureen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Resist Infec Control</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="4" to="14" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Investigators from the REIPI/ESGBIS/INCREMENT Group. β-Lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: a multinational, pre-registered cohort study</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gutiérrez-Gutiérrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pérez-Galera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Salamanca</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="4159" to="4169" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">X</forename><surname>Khong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Harris</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0153696</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">e0153696</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-Lactamase bacteremia</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Tamma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rock</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/civ003</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1319" to="1325" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ofer-Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Shefler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sharma</surname></persName>
		</author>
		<idno type="DOI">10.1017/ice.2015.101</idno>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="981" to="985" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Hsih-Yeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yen</forename><forename type="middle">-</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hung-Jen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.diagmicrobio.2014.07.006</idno>
	</analytic>
	<monogr>
		<title level="j">Diagn Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="222" to="226" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-beta-lactamase-producing Escherichia coli</title>
		<author>
			<persName><forename type="first">P</forename><surname>Retamar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>López-Cerero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Muniain</surname></persName>
		</author>
		<idno type="DOI">10.1128/AAC.00135-13</idno>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="3402" to="3404" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies</title>
		<author>
			<persName><forename type="first">E</forename><surname>Von Elm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Egger</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(07)61602-X</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="1453" to="1457" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Klastersky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Paesmans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Rubenstein</surname></persName>
		</author>
		<idno type="DOI">10.1200/jco.2000.18.16.3038</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="3038" to="3051" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Stout</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="791" to="797" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data</title>
		<idno>23/11/1995 P. 0031-0050EU</idno>
	</analytic>
	<monogr>
		<title level="j">Official Journal L</title>
		<imprint>
			<biblScope unit="volume">281</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns</title>
		<author>
			<persName><forename type="first">K</forename><surname>Hussein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sprecher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mashiach</surname></persName>
		</author>
		<idno type="DOI">10.1086/598244</idno>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="666" to="671" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies</title>
		<author>
			<persName><forename type="first">G</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Huprikar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Factor</surname></persName>
		</author>
		<idno type="DOI">10.1086/592412</idno>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="1099" to="1106" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Antibacterial Resistance Leadership Group. Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumonia infections</title>
		<author>
			<persName><forename type="first">C</forename><surname>Hauck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cober</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Richter</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cmi.2016.01.023</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="513" to="519" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tumbarello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Viale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Viscoli</surname></persName>
		</author>
		<idno type="DOI">10.1093/cid/cis588</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="943" to="950" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
